In a subsequent trial with four DMD patients carrying point mutations, a different protocol was used (two 6-day cycles of gentamicin sulfate, at an interval of 7 weeks) and the result revealed dystrophin expression in three out of four patients with a UGA mutation (23). The gene discussed is DMD; the disease is Duchenne muscular dystrophy.